Calls Still Hot As NIKE, Inc. (NKE) Stays Near All-Time Highs

Nike Inc (NYSE:NKE) quietly hit an all-time high on Monday, and today's call buyers are betting on more upside

by Josh Selway

Published on May 20, 2015 at 3:38 PM

At $104.72, Nike Inc (NYSE:NKE) is 0.1% higher today, and options bulls are stepping up. Data shows call volume at twice the expected intraday pace, with 13,000 of the contracts changing hands so far, compared to fewer than 2,700 puts. There's likely buy-to-open activity occurring at the in-the-money June 103 call, as traders bet on NKE to continue its ascent above $103 through the close on Friday, June 19, when front-month options expire.

It's not uncommon to see the equity's option traders focused on calls. According to NKE's Schaeffer's put/call open interest ratio (SOIR) of 0.78, call open interest outweighs put open interest among options expiring within the next three months. Plus, the reading points to a stronger-than-usual preference for calls over puts, since it falls in the 35th annual percentile.

The majority of analysts are on the bullish side of the fence with it comes to NKE. The stock boasts 13 "buy" or better ratings, eight "holds," and no "sells." And it's no wonder, given the equity's 41.5% year-over-year lead. What's more, it just hit an all-time best of $105.50 on Monday. Against this backdrop, Nike Inc's (NYSE:NKE) 14-day Relative Strength Index (RSI) of 68 is closing in on overbought territory, suggesting a near-term pullback may be in the cards.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.
Patent Lawsuit Loss Sends AMRN Stock Spiraling
Amarin just lost a major U.S. patent lawsuit for its heart drug Vascepa
RH Stock Sinks Despite Earnings Beat
J.P. Morgan Securities and Cowen and Company cut their price targets
The Latest Investor's Guide to Precious Metals
Learn how to protect savings and maximize returns by investing in precious metals.